3-aminobenzamide has been researched along with Diabetic Cardiomyopathies in 1 studies
Diabetic Cardiomyopathies: Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Waldman, M | 1 |
| Nudelman, V | 1 |
| Shainberg, A | 1 |
| Abraham, NG | 1 |
| Kornwoski, R | 1 |
| Aravot, D | 1 |
| Arad, M | 1 |
| Hochhauser, E | 1 |
1 other study available for 3-aminobenzamide and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
PARP-1 inhibition protects the diabetic heart through activation of SIRT1-PGC-1α axis.
Topics: Animals; Cells, Cultured; Diabetic Cardiomyopathies; Enzyme Inhibitors; Glucose; Heart; Hypertension | 2018 |